AlgoraeOS
exploratoryplatform · high · Wed Nov 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Predict and prioritize drug combinations, including dose-specific inhibition profiles, for cancer and other complex diseases using AI-powered drug discovery.
Biologically informed, attention-aware deep neural network trained on harmonized experimentally tested drug-combination datasets; predicts multiple synergy metrics, dose-response surfaces, and uncertainty estimates, with prospective in vitro validation.
Prospective in vitro validation using an anchor compound absent from training, combined with 24 partner drugs across three cancer cell lines for 2,592 dose-combination measurements.
Reported state-of-the-art performance, out-of-distribution generalisability, Spearman rho 0.51-0.59, Kendall tau 0.863, and higher concordance for lower-uncertainty predictions.
DIABECELL for type 1 diabetes mellitus
phase 1drug program · medium · Thu Nov 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate efficacy and safety of xenotransplantation of immunoprotected porcine islets in patients with established type 1 diabetes mellitus.
Open-label clinical investigation using alginate-encapsulated neonatal porcine islets implanted under xenotransplantation regulatory oversight.
Clinical trial record published for open-label safety and efficacy investigation in type 1 diabetes mellitus.
Publication excerpt describes a phase 1/2a xenotransplantation study under New Zealand regulations, but supplied material does not provide detailed outcomes.
AlgoraeRx generic and specialty medicines program
undisclosedother · medium
Source, register, and supply generic and specialty medicines for Australian and New Zealand markets through manufacturer partnerships.
Commercial sourcing, registration, and supply program for generic and specialty medicines.
AlgoraeRx division described as sourcing, registering, and supplying medicines for Australia and New Zealand.
NTCELL for Parkinson's disease
phase 2drug program · high
Assess safety and efficacy of xenotransplantation of immunoprotected porcine choroid plexus cells in patients with Parkinson's disease.
Stereotactic intra-striatal delivery of alginate-encapsulated porcine choroid plexus cells; open-label and randomized double-blind placebo-controlled dose-ranging clinical studies with long-term follow-up.
Long-term follow-up to week 104 after implantation reported no significant clinical benefit.
Phase IIb study did not meet the primary efficacy endpoint at 26 weeks; long-term follow-up showed no significant UPDRS part III improvement at week 104 and no evidence of xenogeneic viral transmission.
